Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inspire Denufosol Phase II Cystic Fibrosis Data Support Early Use, Firm Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Inspire is hoping to expedite moving its cystic fibrosis therapy, INS-37217, into Phase III following better-than-expected Phase II results.

You may also be interested in...

First Cystic Fibrosis Drugs To Target Underlying Genetic Defect Are In Phase II

The first cystic fibrosis drugs to mitigate the ion transport defect underlying the disease are in Phase II, with the support of the Cystic Fibrosis Foundation’s extensive therapeutics development program.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts